Emerald Gate Charitable Trust

Emerald Gate Charitable Trust is a UK-based philanthropic organization and investment vehicle founded by entrepreneur Christian Angermayer. The trust focuses on the preservation of the mind, primarily investing in and supporting life science companies dedicated to mental health and longevity. It is most recognized as a major shareholder in ATAI Life Sciences, a leading developer of psychedelic-based therapies for treatment-resistant depression and other mental health disorders. Additionally, the trust supports research into age-related diseases and the advancement of biotechnology through strategic capital allocation. By bridging the gap between philanthropy and venture capital, Emerald Gate aims to accelerate the delivery of transformative medical solutions.